463 patents
Page 12 of 24
Utility
CD6 Targeted Chimeric Antigen Receptors for Treatent of Certain Autoimmune Disorders
23 Dec 21
Provided herein are, inter alia, CD6 targeting CAR-T cell compositions and methods useful for treating autoimmune diseases (e.g., Type I diabetes).
Jose Enrique Montero Casimiro, Bart Otto Roep, Christine E. Brown
Filed: 1 Jul 19
Utility
PHOSPHOROTHIOATE-CONJUGATED miRNAs AND METHODS OF USING THE SAME
16 Dec 21
Provided herein are, inter alia, nucleic acid conjugates including a non-cell penetrating ribonucleic acid compound attached at its 3′ end to a phosphorothioate polymer.
Andreas Herrmann, Hua Yu
Filed: 30 Mar 21
Utility
Bi-specific Targeted Chimeric Antigen Receptor T Cells
16 Dec 21
T cells expressing a chimeric antigen receptor and a T cell receptor specific for CMV (bi-specific T cells) are described as a methods for using such cells in immunotherapy.
Xiuli Wang, Stephen J. Forman, Don J. Diamond
Filed: 4 Jan 21
Utility
Chimeric antigen receptors targeting HER2
14 Dec 21
Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain targeted to HER2, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.
Saul J. Priceman, Stephen J. Forman, Christine E. Brown
Filed: 4 Nov 16
Utility
DNA2 inhibitors for cancer treatment
14 Dec 21
Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
Filed: 13 Jan 20
Utility
Oxabicycloheptanes for Enhancing Car T Cell Function
9 Dec 21
The present invention provides a method of enhancing the function of CAR T cells comprising administering to the CAR T cells a PP2A inhibitor and optionally one or more anti-cancer therapies.
John S. KOVACH, Stephen J. FORMAN, Xiuli WANG
Filed: 13 Jun 19
Utility
Silica nanoparticle with an insoluble drug
7 Dec 21
Disclosed herein, inter alia, are nanoparticle compositions (e.g., silica nanoparticles) including insoluble drug nanocrystals and methods of using the same for treating cancer.
Pamela Tiet, Jacob Berlin
Filed: 2 Feb 18
Utility
Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies
30 Nov 21
In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof.
John C. Williams, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
Filed: 22 Feb 17
Utility
CTLA-4 aptamer conjugates
30 Nov 21
Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells.
Hua Yu, Andreas Herrmann, Marcin Tomasz Kortylewski
Filed: 4 Jun 20
Utility
IL-6 signaling and breast cancer
30 Nov 21
The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.
Peter P. Lee
Filed: 22 Oct 19
Utility
Splice Inhibiting Oligonucleotides
25 Nov 21
Provided herein are, inter alia, oligonucleotides, kits, and methods useful for increasing lentiviral titers.
John C. Burnett, Elizabeth Epps, John J. Rossi
Filed: 28 Jul 21
Utility
Methods of quantifying N
23 Nov 21
Methods of quantifying a N2-(1-carboxyethyl)-2′-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer.
Samuel Rahbar, Timothy W. Synold, John Termini, Gerald Wuenschell, Daniel Tamae
Filed: 2 Feb 18
Utility
PDGFR RNA aptamers
23 Nov 21
Provided herein, inter alia, are nucleic acid compounds capable of binding PDGFR-a on a cell and internalizing into said cell.
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 15 Oct 15
Utility
Parg Inhibitors and Method of Use Thereof
18 Nov 21
Provided herein are, inter alia, methods of treating cancer using compounds of the invention.
Xiaochun Yu, Shih-Hsun Chen, David Horne, Jun Xie
Filed: 25 Jul 19
Utility
Methods of Islet Cell Culture
18 Nov 21
Provided herein are, inter alia, methods, compositions, and kits for culturing and improving the quality of islet cells.
Jose Enrique Montero CASIMIRO, Bart Otto ROEP, Ismail H. AL-ABDULLAH
Filed: 26 Jun 18
Utility
Hand-held grasping device
16 Nov 21
A hand tool has a pivot connection pivotally attaching a first arm to a second arm, with the pivot connection fixed relative to the first arm and movable to first and second positions relative to the second arm.
David Wong, Anthony Le, Gagandeep Singh, H. Lawson Fisher, James McCrea
Filed: 20 Aug 15
Utility
Remote Rehabilitation System
11 Nov 21
Methods and systems are described for a remote rehabilitation system.
Yuman Fong, Lily L. Lai, Jennifer Hayter, Sherry Hite, Jamie Rand
Filed: 6 May 21
Utility
FOXM1 modulators and uses thereof
9 Nov 21
Disclosed herein, inter alia, are FOXM1 modulators and methods for modulating the activity of androgen receptors in neuronal cells to treat various diseases, such as spinal-bulbar muscular atrophy, amyotrophic lateral sclerosis, and Alzheimer's disease.
Jeremy Jones, Maya Otto-Duessel
Filed: 1 Aug 17
Utility
BAFF-R targeted chimeric antigen receptor-modified t-cells and uses thereof
2 Nov 21
Provided herein are T cells expressing a chimeric antigen receptor (CAR) targeted to B cell activating factor receptor (BAFF-R).
Hong Qin, Larry W. Kwak
Filed: 6 Jun 17
Utility
CCR7 Aptamers and Uses Thereof
28 Oct 21
Disclosed herein are CCR7 aptamers that specifically bind to and internalize into CCR7-expressing cells.
John J. ROSSI, Jiehua ZHOU, Mayumi TAKAHASHI
Filed: 13 May 21